CURRENT APPROACHES TO TREATING UTERINE MYOMA


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Objective. To draw the portrait of a patient with myoma in order to choose therapy that preserves the ovarian reserve. Subjects and methods. There were 19 myoma patients receiving esmya as preoperative preparation or therapy under the control of general clinical, hormonal, and ultrasound examinations. Results. Esmya lessens risksfor postoperative complications and makes it possible to refuse surgery; therapy cycles reduce myoma sizes, by preserving the ovarian reserve. Conclusion. Ulipristal acetate lowers blood loss and a risk for postoperative complications and preserves the ovarian reserve, promoting the use of selective progesterone receptor modulators as the therapy of choice in patients with unsolved reproductive function.

Full Text

Restricted Access

About the authors

Lyudmila Urievna Karakhalis

Kuban State Medical University, Ministry of Health of Russia

Email: lomela@mail.ru
Doctor of Medicine, Professor of the Department of Obstetrics, Gynecology, and Perinatology Krasnodar 350007, Sedina str. 4, Russia

Elena Ivanovna Dubinina

"Rozhdestvenskaya" Clinic

Email: r.klinika@mail.ru
obstetrician-gynecologist, Director Krasnodar 350000, 70 let Oktyabrya str. 1/1, Russia

Nelly Seigeevna Popova

Ekaterininskaya" Clinic

Email: a.papov@mail.ru
post-graduate of the the Department of Obstetrics, Gynecology, and Perinatology Krasnodar 350000, Yatskogo str. 2/2, Russia

Natalia Vladimirovna Bittar

Prof. S.V. Ochapovsky Territorial Clinical Hospital One, Ministry of Health of the Krasnodar Territory

Email: bictar.nat@mail.ru
obstetrician-gynecologist Krasnodar 350086, 1-go Maya str. 167, Russia

Elena Anatolievna Zhuravleva

Timashevsk Central District Hospital

Email: zhuravleva.e20l3@yandex.ru
obstetrician-gynecologist Krasnodar region, Timashevsk 352700, Lenina str. 175, Russia

Olga Vitalievna Turichenko

Teritorial Clinical Hospital Two, Perinatal Center, Territorial Center for Perinatal Diagnosis, Ministry of Health of the Krasnodar Territory

Email: turichenko.olya@yandex.ru
ultrasonography physician, PhD Krasnodar 350000, Krasnykh Partizan str. 6/2, Russia

References

  1. Адамян Л.В., Козаченко Н.В., Ревазова З.В. Новые подходы к медикаментозному лечению симптомной миомы матки (обзор литературы). Проблемы репродукции. 2013; 19(3): 21-3.
  2. Gupta SJose J., Manyonda I. Clinical presentation of fibroids. Best Pract. Res. Clin. Obstet. Gynaecol. 2008; 22(4): 603-14.
  3. Horak P, Mara M., Dundr P, Kubinova K, Kuzel D., Hudecek RChmel R. Effect of a selective progesterone receptor modulator on induction of apoptosis in uterine fibroids in vivo. Int. J. Endocrinol. 2012; 2012: 436174.
  4. Stewart E.A. Uterine fibroids and evidence-based medicine - not an oxymoron. N. Engl. J. Med. 2012; 366(5): 471-3.
  5. Wallach E.E., Vlahos N.E Uterine myomas: an overview of development, clinical features, and management. Obstet. Gynecol. 2004; 104(2): 393-406.
  6. Wise L.A., Palmer J.R., Stewart E.A., Rosenberg L. Age-specific incidence rates for self-reported uterine leiomyoma in the Black Women’s Health Study. Obstet. Gynecol. 2005; 105(3): 563-8.
  7. Make G.P, Andersen J., Dixon D. Etiology and pathogenesis of uterine leiomyomas: a review. Environ. Health Perspect. 2003; 111(8): 1037-54.
  8. Ohara N., Morikawa A., Chen W., Wang J., DeManno D.A., Chwalisz K., Мато T. Comparative effects of SPRM asoprisnil (J867) on proliferation, apoptosis, and the expression of growth factors in cultured uterine leiomyoma cells and normal myometrial cells. Reprod. Sci. 2007; 14(8,Suppl.): 20-7.
  9. Parker W.H. Etiology, symptomatology, and diagnosis of uterine myomas. Fertil. Steril. 2007; 87(4): 725-36.
  10. Payson M., Leppert P, Segars J. Epidemiology of myomas. Obstet. Gynecol. Clin. North Am. 2006; 33(1): 1-11.
  11. Карахалис Л.Ю. Репродуктивная система женщин в различные возрастные периоды жизни: автореф. дисс.. д-ра мед. наук. М.; 2007. 46с.
  12. Карахалис Л.Ю. Репродуктивный потенциал и его влияние на состояние репродуктивного здоровья женщин 45-55 лет. Кубанский научный медицинский вестник. 2006; 1-2: 30-5.
  13. Карахалис Л.Ю., Федорович О.К. Влияние экстрагенитальной, гинекологической патологии в позднем репродуктивном возрасте и перименопаузе в позднем репродуктивном возрасте. Кубанский научный медицинский вестник. 2006; 3-4: 45-50.
  14. Viswanathan M., Hartmann K, McKoy N., Stuart G., Rankins N., Thieda P et al. Management of uterine fibroids: an update of the evidence. Evid. Rep. Technol. Assess. (Full Rep.). 2007; (154): 1-122.
  15. Chabbert-Buffet N., Meduri G., Bouchard P, Spitz I.M. Selective progesterone receptor modulators and progesterone antagonists: mechanisms of action and clinical applications. Hum. Reprod. Update. 2005; 11(3): 293-307.
  16. Chabert-Buffet N. Pintiaux-KairisA., Bouchard P Effects of the progesterone receptor modulator VA2914 in continuous low dose on the hypothalamic- pituitary-ovarian axis and endometrium in normal women: a prospective, randomized, placebo-controlled trial. J. Clin. Endocrinol. Metab. 2007; 92(9): 3582-9.
  17. Madauss K.P., Grygielko E.T., DengS.J., Sulpizio A.C., Stanley T.B., Wu C. et al. A structural and in vitro characterization of asoprisnil: a selective progesterone receptor modulator. Mol. Endocrinol. 2007; 21(5): 1066-81.
  18. Spitz I.M. Clinical utility of progesterone receptor modulators and their effect on the endometrium. Curr. Opin. Obstet. Gynecol. 2009; 21(4): 318-24.
  19. Vollenhoven B.J., Pearce P, Herington A.C., Healy D.L. Steroid receptor binding and messenger RNA expression in fibroids from untreated and gonadotrophin-releasing hormone agonist pretreated women. Clin. Endocrinol. (Oxford). 1994; 40(4): 537-44.
  20. Donnez J., Tatarchuk ТЕ, Bouchard P, Puscasiu L., Zakharenko N.F., Ivanova T. et al. Ulipristal acetate versus placebo for fibroid treatment before surgery. N. Engl. J. Med. 2012; 366(5): 409-20. (PEARL I).
  21. Donnez J., Tomaszewski J., Vazquez F, Bouchard P, Lemieszczuk B., Bard F. et al. Ulipristal acetate versus leuprolide acetate for uterine fibroids. N. Engl. J. Med. 2012; 366(5): 421-32. (PEARL II).
  22. McKeage K, Croxtall J.D. Ulipristal acetate: a review of its use in emergency contraception. Drugs. 2011; 71(7): 935-45.
  23. Spitz I.M. Progesterone receptor antagonists. Curr. Opin. Investig. Drugs. 2006; 7(10): 882-90.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies